Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye co ...

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5 to 7 percent of their weight had a 58% lower risk of ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

Weight-loss drugs are increasingly popular among employees but weigh heavily on health-insurance budgets. Popular weight-loss drugs such as Ozempic, Wegovy and Zepbound are a growing factor in ...